MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
AlloVir Long-Term Debt 2011-2026 | ALVR
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt AlloVir
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 16.6 M | 28.2 M | 23.5 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 16.6 M | 22.8 M |
Quarterly Long-Term Debt AlloVir
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.17 M | - | - | - | - | 8.34 M | 16 M | 16.6 M | 19.9 M | 23 M | 25.6 M | 28.2 M | 19.8 M | - | 20.8 M | 23.5 M | 25.1 M | 4.33 M | 5.41 M | 5.46 M | 5.46 M | 5.46 M | 5.46 M | 8.69 M | 8.69 M | 8.69 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 1.17 M | 13.6 M |
Long-Term Debt of other stocks in the Biotechnology industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
273 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
68.2 M | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.42 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
93.3 M | $ 20.29 | -1.98 % | $ 2.56 B | USA |
 |
Aptorum Group Limited
APM
|
130 K | $ 0.8 | -5.3 % | $ 4.36 M | China |
 |
Biophytis SA
BPTS
|
1.83 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
118 M | $ 166.0 | -0.23 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
137 M | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
278 K | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
4.76 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Certara
CERT
|
290 M | $ 7.22 | 2.34 % | $ 1.16 B | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
2.35 M | $ 23.78 | -0.42 % | $ 2.91 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
1.37 M | $ 18.17 | 1.57 % | $ 873 M | USA |
 |
Adverum Biotechnologies
ADVM
|
86 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
175 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
755 K | - | 1052.0 % | $ 415 M | USA |
 |
Eton Pharmaceuticals
ETON
|
5.38 M | $ 17.9 | -1.38 % | $ 459 M | USA |
 |
Exelixis
EXEL
|
173 M | $ 40.5 | -1.29 % | $ 11 B | USA |
 |
Acer Therapeutics
ACER
|
146 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
3.38 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
167 M | - | -24.86 % | $ 820 K | USA |
 |
Galectin Therapeutics
GALT
|
20 K | $ 2.89 | -5.56 % | $ 180 M | USA |
 |
Capricor Therapeutics
CAPR
|
1.49 M | $ 26.3 | -2.08 % | $ 704 M | USA |
 |
Acasti Pharma
ACST
|
410 K | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
28.9 M | $ 1.02 | -0.33 % | $ 74.9 M | USA |
 |
Galecto
GLTO
|
66 K | $ 29.63 | -1.41 % | $ 787 M |  Danmark |
 |
Halozyme Therapeutics
HALO
|
2.14 B | $ 68.58 | -1.82 % | $ 8.22 B | USA |
 |
CureVac N.V.
CVAC
|
25.4 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
31 K | - | 5.93 % | $ 314 M | Canada |
 |
Hoth Therapeutics
HOTH
|
2.71 K | $ 1.0 | -1.47 % | $ 6.38 M | USA |
 |
AgeX Therapeutics
AGE
|
13.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Harmony Biosciences Holdings
HRMY
|
144 M | $ 28.32 | -2.01 % | $ 1.63 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
4 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
9.12 M | - | - | $ 26.5 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.04 M | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
AIkido Pharma
AIKI
|
2.63 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
12.8 M | $ 3.27 | -2.1 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
1.33 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
529 K | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
21.8 M | $ 28.57 | -2.16 % | $ 1.66 B | USA |
 |
Immuron Limited
IMRN
|
175 K | $ 0.75 | -0.69 % | $ 6.46 M |  Australia |
 |
Immunic
IMUX
|
107 K | $ 1.13 | 6.61 % | $ 176 M | USA |
 |
Immunovant
IMVT
|
1.22 M | $ 27.09 | -2.38 % | $ 4.11 B | USA |
 |
Inhibrx
INBX
|
1.11 M | $ 76.39 | -1.42 % | $ 3.6 B | USA |
 |
InMed Pharmaceuticals
INM
|
16 K | $ 0.8 | -2.44 % | $ 1.96 M | Canada |